Product information and disease descriptionProduct descriptionProduct information
Product comparison
13 evidence topics · 11 sources
Donidalorsen: same target, different oligonucleotide mechanism
Donidalorsen: plasma prekallikrein reduction in OASIS-HAE
Donidalorsen: attack-free rate and dosing frequency as described by the sponsor of onvuzosiran
Donidalorsen: mean attack rate per four weeks in OASIS-HAE
| Treatment | Attack rate |
|---|---|
| Donidalorsen every four weeks | “0.44”View highlighted excerpt for this quote |
| Donidalorsen every eight weeks | “1.02”View highlighted excerpt for this quote |
| Placebo | “2.26”View highlighted excerpt for this quote |
Approved prophylactic agents: limitations described by the sponsor of onvuzosiran
Competing prekallikrein siRNA BW-20805: phase 1 in healthy volunteers
Competing prekallikrein siRNA BW-20805: phase 2 in participants with HAE
Lonvoguran ziclumeran: KLKB1 gene knockout
Network meta-analysis of approved prophylactic agents: time-normalized attack rate
“Additional relative effect estimates showed a statistically significant reduction in the rate of attacks for garadacimab compared with every treatment other than lanadelumab 300 Q2W (Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Lanadelumab 300 Q2W showed statistically significant reductions compared with lanadelumab 300 Q4W, berotralstat, and placebo (Fig. 8).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Treatment | Probability of being best (%) | SUCRA (%) |
|---|---|---|
| Garadacimab 200 mg once monthly | “73”View highlighted excerpt for this quote | “94”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks | “26”View highlighted excerpt for this quote | “83”View highlighted excerpt for this quote |
| Subcutaneous C1INH 60 IU/kg twice weekly | “1”View highlighted excerpt for this quote | “62”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks | “0”View highlighted excerpt for this quote | “40”View highlighted excerpt for this quote |
| Berotralstat 150 mg once daily | “0”View highlighted excerpt for this quote | “20”View highlighted excerpt for this quote |
Network meta-analysis of approved prophylactic agents: attack-free participants
“The fixed-effect model showed that four active treatments, garadacimab, lanadelumab 300 Q2W, lanadelumab 300 Q4W, and subcutaneous C1INH, statistically significantly increased the proportion of attack-free patients compared with placebo (Fig. 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Additional relative effect estimates between the active treatments did not demonstrate statistically significant results (Fig. 10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Network meta-analysis of lanadelumab and berotralstat: attack rate per 28 days
“In this NMA, lanadelumab 300 mg administered every 2 weeks or every 4 weeks was associated with statistically significantly higher effectiveness versus berotralstat 150 mg once daily (q.d.) or 110 mg q.d. for both efficacy outcomes assessed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
| Comparison | Rate ratio (95% CI); p-value |
|---|---|
| Lanadelumab 300 mg every 2 weeks vs berotralstat 150 mg once daily | “0.23 (0.10, 0.55); p = 0.0009”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks vs C1-INH 1000 IU twice weekly | “0.27 (0.11, 0.64); p = 0.0032”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 2 weeks vs placebo | “0.13 (0.06, 0.29); p < 0.0001”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks vs berotralstat 150 mg once daily | “0.48 (0.25, 0.94); p = 0.0311”View highlighted excerpt for this quote |
| Lanadelumab 300 mg every 4 weeks vs placebo | “0.27 (0.15, 0.47); p < 0.0001”View highlighted excerpt for this quote |
Cross-trial comparison limitations
“Following the assessment of NMA feasibility, residual heterogeneity between trials may have persisted, despite our best efforts to minimize bias by excluding insufficiently similar trials and/or trial data.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All trials were placebo controlled, rather than head-to-head, which further simplified network structures.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These network characteristics increase the potential for biased treatment effect estimates, which limits the robustness of the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote